Endogenex Welcomes New Chief Financial Officer
Endogenex, Inc., a clinical-stage medical device company, is delighted to announce the appointment of Krissy Wright as Chief Financial Officer (CFO). Krissy's extensive background in finance, corporate development, and operations is set to bolster the leadership team's capability as they drive the company's ambitious plans in clinical innovation.
Leadership Team Growth
CEO Stacey Pugh expressed enthusiasm over Krissy's addition, noting the critical role her expertise will play in navigating the complexities of the MedTech industry. Wright's financial acumen is particularly valuable as Endogenex strives to achieve its goals in developing transformative solutions for type 2 diabetes management.
Experience and Expertise
Prior to joining Endogenex, Krissy Wright served as the CFO at Cleerly, a leading AI heart diagnostics enterprise. Her impressive track record also includes significant leadership positions at Medtronic, where she was Vice President and General Manager of Brain Modulation, as well as the financial oversight role for the Neuromodulation Operating Unit. With over a decade at PricewaterhouseCoopers, she brings rich experience in Audit, Assurance, and Transaction services, enhancing her capability to guide Endogenex.
A Vision for the Future
In expressing her excitement about her new position, Wright stated, "Joining Endogenex at this pivotal moment is an incredible opportunity. The innovative solutions we are developing for managing type 2 diabetes hold the potential to transform lives globally. I am eager to apply my financial skills to help advance these therapies as we aim to provide significant and scalable healthcare benefits."
The ReCET Procedure Explained
Endogenex is currently evaluating a groundbreaking treatment method known as the ReCET Procedure. This novel, endoscopic, outpatient technique targets cellular abnormalities in the duodenum that can contribute to type 2 diabetes onset and progression. By utilizing highly controlled, non-thermal pulsed electric fields, the ReCET Procedure seeks to initiate natural regenerative processes and restore proper signalling within bodily cells, improving glycemic control effectively.
Advancements and Trials
This innovative approach is undergoing rigorous global pre-commercial trials to investigate its safety and efficacy for adults with type 2 diabetes who are not adequately controlled with existing insulin and non-insulin therapies. The procedure has gained Breakthrough Device Designation from the FDA, highlighting its potential significance in treating patients inadequately managed by current glucose-lowering medications.
About Endogenex
Endogenex operates as a privately held, clinical-stage company focused on pioneering therapeutic solutions aimed at enhancing the quality of life for individuals dealing with type 2 diabetes. Founded in collaboration with Mayo Clinic, Endogenex is committed to exploring treatments that go beyond standard pharmaceutical methods. Their goal is to effectively correct metabolic functions, allowing patients the opportunity to regain control over their blood glucose levels.
Frequently Asked Questions
What is the ReCET Procedure?
The ReCET Procedure is an innovative outpatient treatment aimed at addressing cellular abnormalities in the duodenum to aid in managing type 2 diabetes.
Who is Krissy Wright?
Krissy Wright is the newly appointed Chief Financial Officer of Endogenex, bringing significant experience in finance and corporate leadership within the MedTech industry.
What is the mission of Endogenex?
Endogenex aims to develop therapies that improve outcomes for individuals living with type 2 diabetes by focusing on comprehensive treatment strategies beyond medication.
How does the ReCET Procedure work?
The ReCET Procedure uses non-thermal pulsed electric fields to initiate natural regenerative processes, aimed at improving glycemic control.
Where is Endogenex based?
Endogenex is headquartered in Minneapolis, MN, and operates as a clinical-stage medical device company.
